Emergency Remote Teaching and Digital Technology Usage in K-12 Teacher Practice
Summary
This study seeks to explore how Emergency Remote Teaching (ERT) during COVID-19 has impacted digital technology use in current K-12 teacher practice. Participation in the survey is completely voluntary and will take approximately 20 minutes.
At the end of the survey, participants will be directed to a separate form only if they are interested in participating in the second phase of the study: an online interview (in Zoom) with Amber Hartwell. If a participant provides his/her/their name and email address to express interest in participating in the second phase of the study, they will be contacted to schedule a time that is convenient for them and be provided with the consent form prior to the interview.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 20 to 99
Accepts healthy participants: Yes
Inclusion criteria:
Participants must:
- be enrolled in graduate studies coursework in the Werklund School of Education in Fall 2022
- be a K-12 teacher
- have a minimum of two years of teaching experience
- has experienced a minimum of one cycle of ERT between March 2020 and September 2022. For the context of this case, one cycle of ERT is defined as transitioning from in-person, to ERT, and back to in-person teaching.
Exclusion criteria:
Participants who are not eligible include those:
- with less that two years of K-12 teaching experience
- not enrolled in graduate studies coursework in the Werklund School of Education in Fall 2022
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Amber Hartwell (Doctoral Candidate), Werklund School of Education, University of Calgary
Principal investigator:
Barbara Brown
Clinical trial:
No
REB-ID:
REB22-0481